LHLynn M. Hartweck

Lynn M. Hartweck

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lynn M. Hartweck has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Multimodality Molecular Profiling Nominates Targetable Mechanisms in Progressive RV Dysfunction

    by Madelyn J. Blake, Jenna B. Mendelson, Jacob D. Sternbach, Minwoo Kim, Rashmi M. Raveendran, Ryan A. Moon, Lynn M. Hartweck, Walt Tollison, John P. Carney, Todd Markowski, et al.

    BACKGROUND: Right ventricular dysfunction (RVD) is a robust predictor of mortality in multiple cardiovascular diseases. Currently, it remains unclear whether the severity of RVD corresponds to distinct cellular and molecular alterations, and this has important implications for defining optimal therapeutic targets. To address this knowledge gap, we performed a multiomic evaluation of pulmonary artery banded pigs with differing degrees of right ventricular (RV) compromise. METHODS: Pulmonary artery banded pigs were stratified into mild and severe RVD groups based on RV ejection fraction (mild RVD, 38±4%; severe RVD, 20±8%). RV tissue from control, mild RVD, and severe RVD animals was analyzed using single-nucleus RNA sequencing, mitochondrial and cytoplasmic proteomics, and phosphoproteomics. Histological analyses corroborated multiomic findings. RESULTS: Cardiac magnetic resonance imaging revealed progressive structural and functional alterations in mild and severe RVD pigs. Single-nucleus RNA sequencing demonstrated that advancing RVD was associated with loss of cardiomyocytes, accumulation of efferocytosis-impaired macrophages, and dysregulated endothelial cells and pericytes. Combined transcriptomic and proteomic analyses showed escalating impairments of complex cardiomyocyte metabolism with worsening RVD. RV microvasculature was compromised with severe RVD as there were alterations in endothelial cell/pericyte genetic regulation, colocalization patterns in RV sections, and increased cardiomyocyte HIF1A (hypoxia-inducible factor 1 alpha) transcript expression. Analysis of both mitochondrial and global proteostasis revealed greater compromise in mitochondrial proteostasis, including downregulation of mitochondrial proteases, chaperones, and ribosomes. Paradoxically, cytoplasmic ribosomes were upregulated in severe RVD. The predicted kinome and phosphatome were uniquely altered in mild RVD as compared with severe RVD. Finally, integration of multiomic approaches identified activation of the ribotoxic stress response, impaired macrophage efferocytosis, and insufficient mitochondrial unfolded protein response as potential contributors to severe RVD. Multispecies comparison suggested that the ribotoxic stress response was the most conserved pathogenic response in RVD. CONCLUSIONS: Our multiomic analysis defines the cellular and molecular landscape of progressive RVD and nominates druggable pathways that may promote progressive RVD. Future studies are needed to determine how engaging these pathways influences RV phenotypes.


  • Open Access

    Pulmonary Arterial Hypertension Induces a Metabolic and Inflammatory Hepatopathy

    by Madelyn J. Blake, Sally E. Prins, Jeffrey C. Blake, Lynn M. Hartweck, Jenna B. Mendelson, Steeve Provencher, Sandra Breuils-Bonnet, Sebastien Bonnet, Kurt W. Prins

    BACKGROUND. Right ventricular failure (RVF) is a major determinant of mortality in pulmonary arterial hypertension (PAH), and hepatic dysfunction predicts adverse outcomes. However, the cell-specific effects of PAH/RVF on the human liver remain poorly defined. METHODS. We performed single-nucleus RNA sequencing of autopsy-derived liver tissue from 5 PAH patients and 4 non-PAH controls and compared these findings with publicly available single-nucleus RNA sequencing datasets from non-alcoholic steatohepatitis (NASH) and Fontan-associated liver disease (FALD). Transcriptomic analyses were integrated with histologic assessment, mitochondrial-enriched proteomics, and correlated with clinical markers of PAH/RVF severity. RESULTS. PAH livers showed cell-specific metabolic, inflammatory, and fibrotic remodeling distinct from NASH and FALD. PAH hepatocytes exhibited a hypoxia-adapted, Warburg-like metabolic phenotype with reduced fatty acid metabolism, gluconeogenesis, cytochrome P450 activity, and ketone metabolism. PAH endothelial cells demonstrated increased glycolytic pathway activity and disrupted adhesion/barrier signaling. PAH hepatic stellate cells displayed HIF-1 and PI3K-Akt pathway activation, and increased IL6 expression, which resulted in central vein fibrotic remodeling. PAH macrophages showed complement activation with reduced JAK-STAT signaling. Finally, HSC HIF-1 activity correlated with clinical markers of PAH/RVF severity. CONCLUSION. PAH induces a distinct metabolic and inflammatory hepatopathy characterized by hepatocyte metabolic reprogramming, HSC activation, and macrophage complement signaling. These findings support PAH-associated hepatopathy as a disease-specific end-organ phenotype linked to RVF severity.


  • Open Access

    17β-Estradiol counteracts pathological microtubule remodeling to enhance right ventricular function in preclinical models

    by Ryan A. Moon, Rafael Sobrano Fais, Minwoo Kim, Neal T. Vogel, Jenna B. Mendelson, Lynn M. Hartweck, John P. Carney, Melissa K. Gardner, Sally E. Prins, Sasha Z. Prisco, et al.

    Estrogen exerts cardioprotective effects via microtubule regulation.

  • GP130 Antagonism Enhances Porcine RV Function

    by Jenna B. Mendelson, Jacob D. Sternbach, Minwoo Kim, Ryan A. Moon, Lynn M. Hartweck, Sophia R. Clark, Walt Tollison, Matthew T. Lahti, John P. Carney, Todd Markowski, et al.

    BACKGROUND: Right ventricular (RV) dysfunction is a risk factor for death in multiple cardiovascular diseases, but RV-enhancing therapies are lacking. Inhibition of GP130 (glycoprotein-130) signaling with the small molecule SC144 improves RV function in rodent RV dysfunction via anti-inflammatory and metabolic mechanisms. However, SC144’s efficacy and molecular effects in a translational large animal model of RV dysfunction are unknown. METHODS: Four-week-old castrated male pigs underwent pulmonary artery banding (PAB). After 3 weeks, PAB pigs were randomized into 2 groups (daily injections of SC144 [2.2 mg/kg, PAB-SC144, n=5] or vehicle [PAB-Veh, n=5] for 3 weeks). Five age-matched pigs served as controls. Cardiac magnetic resonance imaging quantified RV size/function. Right heart catheterization evaluated hemodynamics. Single-nucleus RNA sequencing delineated cell-type-specific changes between experimental groups. Electron microscopy evaluated RV mitochondrial morphology. Phosphoproteomics identified dysregulated RV kinases. Lipidomics and metabolomics quantified lipid species and metabolites in RV tissue and serum. Quantitative proteomics examined RV mitochondrial protein regulation. Confocal microscopy evaluated alterations in cardiomyocyte size, macrophage abundances, capillary density, and pericyte/endothelial cell localization patterns. RESULTS: SC144 significantly improved RV ejection fraction (control: 60±4%; PAB-Veh: 22±10%; PAB-SC144: 37±6%) without altering RV afterload. Single-nucleus RNA sequencing demonstrated that PAB-Veh pigs had lower cardiomyocyte and higher macrophage/lymphocyte/pericyte/endothelial cell abundances as compared with control, and many of these changes were blunted by SC144. Immunohistochemistry validated the reduction in RV macrophage infiltration by SC144. Both transcriptomics and proteomics approaches demonstrated that SC144 combatted the downregulation of cardiomyocyte metabolic genes/proteins induced by PAB. Kinome enrichment analysis suggested SC144 counteracted RV mTORC1 (mammalian target of rapamycin complex 1) activation. Correspondingly, SC144 rebalanced the RV autophagy pathway proteins and improved mitochondrial morphology. Integrated lipidomics, metabolomics, and proteomics analyses revealed that SC144 restored fatty acid metabolism. Finally, CellChat analysis, cardiomyocyte RNAseq analysis, and histological examination suggested SC144 rebalanced pericyte-endothelial cell interactions and blunted cardiomyocyte HIF1 (hypoxia-induced factor 1) activation. CONCLUSIONS: GP130 antagonism blunts RV immune cell infiltration, reduces proinflammatory gene programs in macrophages and lymphocytes, rebalances autophagy, and preserves fatty acid metabolism in cardiomyocytes, and restores endothelial cell and pericyte homeostasis to mitigate cardiomyocyte hypoxia and ultimately augments RV function.


  • Single-Nucleus RNAseq Defines Cellular and Molecular Landscape of Dysfunctional Right Atrium in Pulmonary Artery Banded Swine

    by Jenna B. Mendelson, Jacob D. Sternbach, Minwoo Kim, Ryan A. Moon, Jeffrey C. Blake, Rashmi M. Raveendran, Lynn M. Hartweck, Walt Tollison, Matthew Lahiri, John P. Carney, et al.


  • Lactobacillus Restructures the Micro/Mycobiome to Combat Inflammation-Mediated Right Ventricular Dysfunction in Pulmonary Arterial Hypertension

    by Sasha Z. Prisco, Madelyn Blake, Felipe Kazmirczak, Ryan Moon, Benjamin P. Kremer, Lynn M. Hartweck, Minwoo Kim, Neal Vogel, Jenna B. Mendelson, Daphne Moutsoglou, et al.

    BACKGROUND: Inflammation suppresses right ventricular (RV) function in pulmonary arterial hypertension (PAH). In particular, we showed GP130 (glycoprotein-130) signaling promotes pathological microtubule remodeling and RV dysfunction in rodent PAH. Emerging data demonstrate the intestinal microbiome regulates systemic inflammation, but the impact of modulating the gut microbiome on the GP130-microtubule axis in RV failure is unknown. METHODS: Two weeks following monocrotaline injection, rats were administered daily Lactobacillus rhamnosus (4×10 7 colony-forming units) via oral gavage for 10 days. Next-generation metagenomics and internal transcribed spacer 2 sequencing delineated fecal bacterial and fungal compositions. SomaScan proteomics measured levels of 7596 serum proteins. RV immunoblots quantified protein abundances. Light or super resolution confocal microscopy assessed RV, lung, and jejunal morphology. Echocardiography and invasive closed-chest pressure-volume loops evaluated PAH severity and RV function. The relationship between Lactobacillus abundance and RV function was assessed in 65 patients with PAH. RESULTS: Lactobacillus administration restructured both the intestinal micro- and mycobiome. The alteration in the gut ecosystem improved intestinal health as demonstrated by increased jejunal villus length and glycocalyx thickness and diminished intestinal permeability biomarkers. Serum proteomics revealed Lactobacillus modulated systemic inflammation and decreased circulating GP130 ligands. Lactobacillus -mediated suppression of GP130 signaling blunted pathological microtubule remodeling in RV cardiomyocytes. Microtubule-associated phenotypes, including RV cardiomyocyte and nuclear hypertrophy, transverse tubule integrity, and connexin-43 localization, were all corrected with Lactobacillus . These cellular changes manifested as improved RV function despite no significant alteration in PAH severity. Finally, patients with PAH and detectable fecal Lactobacillus had superior RV function despite similar mean pulmonary arterial pressure and pulmonary vascular resistance as compared with those without detectable Lactobacillus . CONCLUSIONS: Lactobacillus supplementation restructures the gut micro/mycobiome, restores intestinal health, dampens systemic inflammation, and reduces GP130 ligands and associated RV cardiomyocyte microtubule remodeling. These data identify a novel microbiome-inflammation-microtubule axis that has therapeutic relevance for RV dysfunction.


  • Open Access

    Estradiol pauses microtubule growth without increased incidence of catastrophe events

    by Allison N. Ogren, Noah J. Zimmerman, Simone Stark, Mark McClellan, Samuel J. Gonzalez, Lynn M. Hartweck, Kurt W. Prins, Melissa K. Gardner

    Microtubules are long filaments that control cellular structure and influence intracellular transport. The female hormone estrogen has been implicated in alterations to the microtubule network for a variety of cell types. However, the effects of estrogen on individual microtubules are unknown. In this work we systematically investigated a mechanism by which estrogen could alter the length dynamics of individual microtubules. Using multi-line cell assays, cell-free experiments, and computational modeling, we found that estradiol acts to frustrate and pause microtubule growth in cells, independent of estrogen receptor pathways. Specifically, estradiol acts as a switch in which dynamic, growing microtubules were transformed into paused, non-growing microtubules. Estradiol pauses microtubule growth without inducing an increased incidence of catastrophe events, similar to the widely used microtubule poison colchicine. We conclude that estrogen’s ability to limit excessive microtubule proliferation could have important implications for therapeutic approaches in heart disease and breast cancer.


  • Top Cited Papers

    Ferroptosis-Mediated Inflammation Promotes Pulmonary Hypertension

    by Felipe Kazmirczak, Neal T. Vogel, Sasha Z. Prisco, Michael T. Patterson, Jeffrey Annis, Ryan T. Moon, Lynn M. Hartweck, Jenna B. Mendelson, Minwoo Kim, Natalia Calixto Mancipe, et al.

    BACKGROUND: Mitochondrial dysfunction, characterized by impaired lipid metabolism and heightened reactive oxygen species generation, results in lipid peroxidation and ferroptosis. Ferroptosis is an inflammatory mode of cell death that promotes complement activation and macrophage recruitment. In pulmonary arterial hypertension (PAH), pulmonary arterial endothelial cells exhibit cellular phenotypes that promote ferroptosis. Moreover, there is ectopic complement deposition and inflammatory macrophage accumulation in the pulmonary vasculature. However, the effects of ferroptosis inhibition on these pathogenic mechanisms and the cellular landscape of the pulmonary vasculature are incompletely defined. METHODS: Multiomics and physiological analyses evaluated how ferroptosis inhibition–modulated preclinical PAH. The impact of adeno-associated virus 1–mediated expression of the proferroptotic protein ACSL (acyl-CoA synthetase long-chain family member) 4 on PAH was determined, and a genetic association study in humans further probed the relationship between ferroptosis and pulmonary hypertension. RESULTS: Ferrostatin-1, a small-molecule ferroptosis inhibitor, mitigated PAH severity in monocrotaline rats. RNA-sequencing and proteomics analyses demonstrated ferroptosis was associated with PAH severity. RNA-sequencing, proteomics, and confocal microscopy revealed complement activation and proinflammatory cytokines/chemokines were suppressed by ferrostatin-1. In addition, ferrostatin-1 combatted changes in endothelial, smooth muscle, and interstitial macrophage abundance and gene activation patterns as revealed by deconvolution RNA-sequencing. Ferroptotic pulmonary arterial endothelial cell damage–associated molecular patterns restructured the transcriptomic signature and mitochondrial morphology, promoted the proliferation of pulmonary artery smooth muscle cells, and created a proinflammatory phenotype in monocytes in vitro. Adeno-associated virus 1- Acsl4 induced an inflammatory PAH phenotype in rats. Finally, single-nucleotide polymorphisms in 6 ferroptosis genes identified a potential link between ferroptosis and pulmonary hypertension severity in the Vanderbilt BioVU repository. CONCLUSIONS: Ferroptosis promotes PAH through metabolic and inflammatory mechanisms in the pulmonary vasculature.


  • Junctophilin-2 Regulates Mitochondrial Metabolism

    by Sasha Z. Prisco, Lynn M. Hartweck, Felipe Kazmirczak, Jenna B. Mendelson, Stephanie L. Deng, Madelyn Blake, Satadru K. Lahiri, Xander H.T. Wehrens, Kurt W. Prins


  • Open Access

    SECRET AGENT O-GlcNAc Modifies GIGANTEA: Methods for Mapping of O-Linked β-N-Acetylglucosamine Modification Sites Using Mass Spectrometry

    by Young-Cheon Kim, Lynn M. Hartweck, Neil E. Olszewski

    Arabidopsis thaliana has two glycosyl transferases, SPINDLY (SPY) and SECRET AGENT (SEC), that modify nuclear and cytosolic protein with O-linked fucose and N-acetylglucosamine (GlcNAc), respectively. SPY interacts physically and genetically with GIGANTEA (GI). Previously, we reported that SEC substrates are O-GlcNAc modified when they are co-expressed in E. coli . By analyzing overlapping sub-fragments of GI, we found a region that was modified by SEC. Mutational mapping of the modified region was then performed. Modification was undetectable when threonine 829 was mutated to alanine (T829A) while the T834A and T837A mutations reduced modification suggesting that T829 was the primary or only modification site. Mapping using several enrichment and mass spectrometry methods all detected only modification of T829.